叔丁氧基羰基-天冬氨酸胺 | 74244-17-0

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 天冬酰胺类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 叔丁氧基羰基-天冬氨酸胺
• 中文别名: 叔丁氧基羰基-L-异天冬酰胺；叔丁氧基羰基-L-天冬氨酸-1-酰胺；N-叔丁氧基羰基异天冬氨酰胺
• 英文名称: (S)-4-amino-3-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid
• 英文别名: N-t-butyloxycarbonyl-L-aspartic acid α-amide；Boc-aspartate；Boc-isoAsn-OH；Boc-Asp-NH2；tert.-Butyloxycarbonyl-L-isoasparagin；(3S)-4-amino-3-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoic acid
• CAS: 74244-17-0
• 化学式: C₉H₁₆N₂O₅
• mdl: MFCD00076946
• 分子量: 232.236
• InChiKey: VKCARTLEXJLJBZ-YFKPBYRVSA-N

物化性质

• 熔点：
  150-154 °C
• 沸点：
  462.7±40.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)
• 稳定性/保质期：

  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• WGK Germany：
  3
• 海关编码：
  2924199090
• 储存条件：
  存放在密封容器内，并置于阴凉、干燥处。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Boc-asp-nh2
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Boc-asp-nh2
CAS number: 74244-17-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H16N2O5
Molecular weight: 232.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

Boc-Asp-NH₂是一种天冬氨酸衍生物[1]。

反应信息

• 作为反应物：
  描述：

  叔丁氧基羰基-天冬氨酸胺 在 potassium tert-butylate 、 ammonium acetate 作用下， 以 四氢呋喃 、 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 8.0h， 生成
  参考文献：
  名称：

  发现和优化有效的和高度亚型的选择性Na v 1.8抑制剂，可降低心血管疾病† ‡

  摘要：

  电压门控钠通道，特别是Na v 1.8，可以靶向治疗神经性和炎性疼痛。在本文中，我们描述了Na v 1.8抑制苯基咪唑系列的发现和优化，该系列可提供具有高效价和选择性并能证明良好的口服药代动力学的化学平衡。

  DOI：

  10.1039/c6md00281a
• 作为产物：
  描述：

  N-t-butyloxycarbonyl-L-aspartic acid β-benzyl ester α-amide 在 5%-palladium/activated carbon 、 氢气 作用下， 以 甲醇 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以80%的产率得到叔丁氧基羰基-天冬氨酸胺
  参考文献：
  名称：

  Heating Reactions of N-t-Butyloxycarbonyl-Asparagine and Related Compounds

  摘要：

  N-叔丁氧羰基氨基酸（Boc-）在加热时不稳定，不能提供游离氨基酸，但 Boc-天冬氨酸可以提供一种多肽。 Boc-天冬氨酸的这种化学特征可能是由两个羧基之间的脱水以及游离氨基的形成引起的。 Boc-天冬酰胺可能与 Boc-天冬氨酸具有相似的反应性。本研究描述了通过加热 Boc-天冬酰胺及其异构体 Boc-天冬氨酸酰胺形成多肽。

  DOI：

  10.14233/ajchem.2014.16493

文献信息

• Exploring Structural Parameters for Pretargeting Radioligand Optimization
  作者：Jan-Philip Meyer、Paul Kozlowski、James Jackson、Kristen M. Cunanan、Pierre Adumeau、Thomas R. Dilling、Brian M. Zeglis、Jason S. Lewis

  DOI：10.1021/acs.jmedchem.7b01108

  日期：2017.10.12

  18F-based pretargeting strategy predicated on the inverse electron demand Diels–Alder reaction as well as the use of this approach to visualize pancreatic tumor tissue in vivo as early as 1 h postinjection. Herein, we report a comprehensive structure: pharmacokinetic relationship study of a library of 25 novel radioligands that aims to identify radiotracers with optimal pharmacokinetic and dosimetric properties

  预靶向提供了一种在降低有效载荷输送过程中对健康组织的脱靶辐射剂量的同时增强靶标特异性的方法。我们最近报告了18基于F的预靶向策略基于逆电子需求Diels–Alder反应以及这种方法的使用，可在注射后1 h内可视化体内胰腺肿瘤组织。在这里，我们报告一个全面的结构：25个新型放射性配体的库的药代动力学关系研究，旨在确定具有最佳药代动力学和剂量学特性的放射性示踪剂。这项研究揭示了分子结构与体内行为之间的关键关系，并产生了两个主要候选物，这些候选物在早期时间点以快速的肿瘤靶向性和较高的靶与背景活性浓度比。我们相信这些知识对于设计和临床翻译用于疾病诊断和治疗的下一代靶向药物具有很高的价值。
• Studies on neurokinin antagonists. 2. Design and structure-activity relationships of novel tripeptide substance P antagonists, N.alpha.-[N.alpha.-(N.alpha.-acetyl-L-threonyl)-N1-formyl-D-tryptophyl]-N-methyl-N-(phenylmethyl)-L-phenylalaninamide and its related compounds
  作者：Daijiro Hagiwara、Hiroshi Miyake、Hiroshi Morimoto、Masako Murai、Takashi Fujii、Masaaki Matsuo

  DOI：10.1021/jm00095a013

  日期：1992.8

  terms of potency and stability. Subsequent modification of the amino terminal into N alpha-acetyl-L-threonine led to the most potent compound, N alpha-[N alpha-(N alpha-acetyl-L-threonyl)-N1-formyl-D-tryptophyl]-N- methyl-N-(phenylmethyl)-L-phenylalaninamide [Ac-Thr-D-Trp(CHO)-Phe-NMeBzl (5a, FR113680)]. This compound 5a potently blocked 3H-SP binding to guinea pig lung membranes with IC50 of (5.8 +/-

  继续研究先前报道的新型三肽SP拮抗剂Nα-[Nα-[Nα-（叔丁氧基羰基）谷氨酰胺基] -N1-甲酰基-D-色氨酸]苯丙氨酸苄酯[Boc-Gln- D-Trp-（CHO）-Phe-OBzl（1）]在本文中描述。我们最初研究了豚鼠血浆和肝脏匀浆中1的稳定性，以阐明结构中最不稳定的部分。结果表明，苄基酯部分易于水解以产生惰性酸类似物。因此，我们搜索了对水解酶更具抗性的苄基酯替代物。该方法发现了等价酰胺结构，N-甲基-N-（苯甲基）酰胺，其效力和稳定性均合适。随后将氨基末端修饰成Nα-乙酰基-L-苏氨酸导致了最有效的化合物Nα-[Nα-（Nα-乙酰基-L-苏氨酸）-N1-甲酰基-D-色氨酸] -N -甲基-N-（苯甲基）-L-苯丙氨酰胺[Ac-Thr-D-Trp（CHO）-Phe-NMeBzl（5a，FR113680）]。该化合物5a有效阻断3H-SP与豚鼠肺膜的结合，IC50为（5.8 +/-
• Conjugates for cancer therapy and diagnosis
  申请人：Gengrinovitch Stela

  公开号：US20070072800A1

  公开（公告）日：2007-03-29

  The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as compositions for treatment of cancer, and conjugates of imaging agent carriers and amino acids for the diagnosis of tumors and metastases.

  本发明涉及药物与氨基酸或氨基酸衍生物或类似物的结合物、包括该结合物的药物组合物以及使用方法。具体来说，本发明涉及抗增殖药物与天冬氨酸、谷氨酸及其类似物的结合物作为治疗癌症的组合物，以及影像剂载体与氨基酸的结合物用于肿瘤和转移瘤的诊断。
• [EN] CATHEPSIN CYSTEINE PROTEASE INHIBITORS FOR THE TREATMENT OF VARIOUS DISEASES<br/>[FR] INHIBITEURS DE LA CATHEPSINE CYSTÉINE PROTÉASE POUR TRAITER DES MALADIES VARIÉES
  申请人：MERCK FROSST CANADA LTD

  公开号：WO2010148488A1

  公开（公告）日：2010-12-29

  The present invention relates to compounds capable of inhibiting and/or decreasing the activity of one or more cathepsins, thereby treating and/or preventing various disease states associated with one or more cysteine proteases including, but not limited to, cathepsins and papain-like cysteine proteases. Disease states treated and/or prevented by the compounds of the invention include, but are not limited to, mammalian parasitic diseases in which the parasite utilizes a critical cysteine protease from the papain family. Examples of parasitic diseases to be treated or prevented by the compounds of the invention include, but are not limited to, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, leishmaniasis, coccidiosis, giardiosis, cryptosporidiosis or schistosomiasis.

  本发明涉及一种能够抑制和/或减少一种或多种半胱氨酸蛋白酶活性的化合物，从而治疗和/或预防与一种或多种半胱氨酸蛋白酶相关的各种疾病状态，包括但不限于cathepsins和木瓜蛋白酶样半胱氨酸蛋白酶。本发明的化合物治疗和/或预防的疾病状态包括但不限于寄生于哺乳动物的寄生病，其中寄生虫利用木瓜家族的关键半胱氨酸蛋白酶。本发明的化合物可用于治疗或预防的寄生病例包括但不限于弓形虫病、疟疾、非洲锥虫病、查加斯病、利什曼病、球虫病、贾第虫病、隐孢子虫病或血吸虫病。
• PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT
  申请人：Kim Bong Chan

  公开号：US20130165659A1

  公开（公告）日：2013-06-27

  The present invention relates to a novel method for preparing a compound of formula (2) as the intermediate, which can be effectively used for preparation of a compound of formula (1) exhibiting good inhibitory activity against dipeptidyl peptidase IV enzyme.

  本发明涉及一种新颖的制备化合物(2)中间体的方法，该中间体可有效用于制备一种具有良好抑制二肽基肽酶IV酶活性的化合物(1)的方法。